Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 19, 2020 at 10:32 AM.

  1. #1 cafead, Nov 19, 2020 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course for regulatory filings next year.

    article source
     
    Quote

Reply to Thread